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Two hallmarks of measles virus (MV) infection are the ability of the virus to cause immunosuppression and the resultant enhanced
susceptibility of the infected host to microbial insults. We investigated the effect of MV infection on the ability of dendritic cells (DCs) to induce
IL-12 via toll-like receptor (TLR) signaling. When infected with MV, transgenic mice which expressed human SLAM receptor on their DCs were
defective in the selective synthesis of IL-12 in DCs in response to stimulation of TLR4 signaling, but not to engagements of TLR2, 3, 7 or 9. MV
suppressed TLR4-mediated IL-12 induction in DCs even in the presence of co-stimulation with another ligand for TLR2, 3, 7, or 9. While MV V
and C proteins were not responsible for IL-12 inhibition, interaction of MV hemagglutinin with human SLAM facilitated the suppression. These
results suggest that MV, by altering DC function, renders them unresponsive to secondary pathogens via TLR4.
© 2006 Published by Elsevier Inc.Keywords: Measles virus; Dendritic cell; SLAM; Toll-like receptor; IL-12; ImmunosuppressionIntroduction
Immunosuppression associated with opportunistic infec-
tions is responsible for most of the current 500,000 measles-
related deaths annually (CDC, 2005; Griffin, 2001). Measles
virus (MV) interferes with the function of dendritic cells (DCs)
by enhancing their apoptosis (Fugier-Vivier et al., 1997; Servet-
Delprat et al., 2000a), upregulating expression of TNF-related
apoptosis-inducing ligand (TRAIL) (Vidalain et al., 2000),
altering CD40 ligand-dependent differentiation (Servet-Delprat
et al., 2000b), inhibiting DC development via STAT2 signaling
(Hahm et al., 2005), and suppressing DC-stimulated prolifera-
tion of T lymphocytes (Dubois et al., 2001; Grosjean et al., 1997;
Klagge et al., 2000; Schnorr et al., 1997). MV was reported to
activate TLR2 signaling (Bieback et al., 2002) and suppress
TLR7 and TLR9-stimulated production of type I IFNs from
plasmacytoid DCs (Schlender et al., 2005). MV infection skews⁎ Corresponding author. Fax: +1 858 784 9981.
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doi:10.1016/j.virol.2006.10.004host immune response towards Th2 phenotype (Griffin and
Ward, 1993). This suppression of Th1-mediated cellular
immune responses was thought to result from the inhibition of
IL-12 synthesis (Karp et al., 1996). Indeed, suppression of IL-12
was reported in MV-infected children (Atabani et al., 2001), in
rhesus macaques during measles (Polack et al., 2002), in MV-
infected transgenic (tg) mice expressing CD46 receptor (Marie
et al., 2001), and in DCs generated from human PBMC when
infected byMV (Fugier-Vivier et al., 1997; Servet-Delprat et al.,
2000b). CD46 and MV nucleoprotein were suggested to play a
role in the inhibition of IL-12 production from monocytes/DCs
(Karp et al., 1996; Marie et al., 2001).
Two cellular receptors CD46 and signaling lymphocyte
activation molecule (SLAM) on human cells were reported to
interact withMV hemagglutinin (HA) permitting viral entry into
cells (Dorig et al., 1993; Manchester et al., 1994; Naniche et al.,
1993; Tatsuo et al., 2000). MV is a human but not a rodent
pathogen. Studies that engineer mice to express the MV
receptors have greatly aided in dissecting the pathogenesis of
this virus. Generation of tg mice expressing human CD46
252 Rapid Communication(Blixenkrone-Moller et al., 1998; Horvat et al., 1996; Mrkic
et al., 1998; Oldstone et al., 1999; Rall et al., 1997) or SLAM
(Hahm et al., 2003, 2004; Sellin et al., 2006; Shingai et al.,
2005; Welstead et al., 2005) has been reported.
Here, we utilize tg mice that express human (h) SLAM on
their DCs (Hahm et al., 2004). Investigation of responses of
MV-infected DCs to various TLR stimulations revealed that
MV significantly inhibited production of IL-12 but not of IL-6
and TNF-α from DCs in response to TLR4 stimulation. This
inhibition of IL-12 was selective for TLR4 signaling as it did
not occur in the presence of signaling by TLR2, TLR3, TLR7,
or TLR9. The interaction of MV HA with hSLAM receptor
contributed to the suppression of IL-12.
Results and discussion
Differential responses of measles virus-infected DCs to TLR
activations in producing cytokines
We previously engineered mice to express human (h) SLAM
on DCs (Hahm et al., 2004). DCs from such mice were suscep-
tible to MV. To examine whether MV affects DC capability of
producing cytokines in response to various TLR activations,
bone marrow (BM)-derived DCs from tg mice were infected
with MV, treated with TLR ligand (L), after which their pro-
duction of cytokines was analyzed. In our in vitro MV infection
analysis, approximately 30% of CD11c+DCswere infected with
MV by FACS. MV-infected DCs were significantly suppressed
in synthesizing IL-12p70/p40 when responding to TLR4
stimulation with pure LPS by FACS (37% of IL-12-producing
cells from control cells vs. 6% fromMV-infected DCs measured
for 5 h at 2 h post LPS treatment; Fig. 1A) or secreted hetero-
dimeric form of IL-12p70 by ELISA analysis (Fig. S1). The
degree in IL-12 suppression was dependent on viral infectivity
of DCs (data not shown). However, IL-12 inhibition was hardly
observed when MV-infected DCs were treated with peptidogly-
can (PGN, TLR2L), poly(I:C) (TLR3L) (data shown in Fig. 2E),
CpG DNA (TLR9L) or loxoribine (TLR7L) (Fig. 1A). TLR4-
mediated IL-12 inhibition was observed 24 h after TLR4
stimulation with the treatment of varying concentrations of LPS
(1 to 1000 ng/ml) in MV-infected DCs (Fig. 1B). MV infection
induced DCs to produce more IL-12 (Fig. 1A) and TNF-α (Fig.
1E) in response to loxoribine treatment compared to mock-
infectedDCs. These results indicated thatMVinfection sensitized
DCs to TLR7 signaling. Two cytokines, Flt3-L and GM-CSF
are critical for DC development, DC survival, and different DC
subset generation (Daro et al., 2002). MV suppressed IL-12
production after TLR4 engagement in DCs generated by either
Flt3-L or GM-CSF-supplemented DC culture systems (Fig. 1C).
DCs from spleens of tg mice infected with MV in vivo
(approximately 10% of DCs were infected with MV) did not
efficiently respond to TLR4 activation to produce IL-12
(Fig. 1D). In contrast, such DCs retained potential to yield IL-12
(Fig. 1D) or TNF-α (data not shown) when they were activated
by CpG DNA, a TLR9L, results consistent with in vitro MV
infection (Fig. 1A). MV targets TLR4 signaling to selectively
suppress IL-12, as TLR4-mediated production of other inflam-matory cytokines such as TNF-α and IL-6 was not diminished in
MV-infected DCs (Fig. 1E and F). Furthermore, TLR4/MD2
complex expression on the surface of DCs hardly changed in
LPS-treated DCs by MV infection (Fig. S2). Collectively, the
data indicates that MV specifically inhibits IL-12 production in
response to TLR4 activation. Molecular mechanisms (Agrawal
et al., 2003; Aste-Amezaga et al., 1998; Reis e Sousa, 2004;
Takeda and Akira, 2004) of MV-induced IL-12 inhibition upon
TLR4 activation remain to be uncovered.
MV suppresses TLR4-mediated IL-12 production even in the
presence of TLR2, TLR3, TLR7, or TLR9 stimulation
Since Gram-negative bacteria contain potential motifs of both
TLR4L (LPS) and TLR9L (CpG DNA), two TLR signaling
pathways could be stimulated on DCs simultaneously by a
pathogenic invasion. When mock-infected DCs were stimulated
with both LPS and CpG DNA at the same time, they enhanced
the production of IL-12 either additively or synergistically
compared to the production by either treatment alone also
confirming the report of Napolitani et al. (2005). Interestingly,
although MV-infected DCs responded to CpG treatment alone
(28% of IL-12 producing cells in Fig. 2A) as seen for mock-
infected DCs, they were suppressed substantially in yielding
IL-12 in response to co-treatment of both LPS and CpG (7%
of IL-12+ cells). Addition of various amount of CpG DNA
(2 ng/ml to 2 μg/ml; Fig. 2B, data not shown) could not restore
IL-12 production from MV-infected DCs in the presence of LPS
(0.1 ng/ml to 1000 ng/ml). Furthermore, pre-treatment of CpG
DNA onto MV-infected DCs 1 h before LPS treatment failed to
induce significant increase in IL-12 synthesis additively, which
was observed in mock-infected DCs (Fig. 2C). As MV repli-
cation makes DCs respond to the engagement of TLR7 by
loxoribine treatment to enhance the production of inflammatory
cytokines, we added both LPS and loxoribine onto MV-infected
DCs and analyzed IL-12 synthesis compared to mock-infected
DCs. Whereas IL-12 was increased in MV-infected DCs in
response to TLR7 activation compared to mock-infected DCs,
IL-12 expression was significantly altered when the cells were
stimulated with ligands for both TLR7 and TLR4 (Fig. 2D).
Similarly, suppression of IL-12 was observed in the combina-
tions of LPS plus either poly(I:C), (TLR3L) or PGN (TLR2L)
(Fig. 2E). Treatment of loxoribine, poly(I:C), or PGN did not
suppress CpG-induced IL-12 production in MV-infected DCs.
MV HA interaction with SLAM receptor contributes to the
suppression of IL-12
MV V and C proteins have been reported to suppress host
immune responses including inhibition of interferon signaling
pathways (Palosaari et al., 2003; Patterson et al., 2000;
Shaffer et al., 2003; Takeuchi et al., 2003). To determine the
role, if any, of MV proteins V or C in the TLR4/IL-12
targeting by MV, we used functional recombinant MV
defective in V [MV-V(−)] or C gene [MV-C(−)] generated by
reverse genetics (Patterson et al., 2000). These mutant viruses
lacking either Vor C genes of measles had the same potential to
Fig. 1. MV inhibits IL-12 production selectively in response to the activation of TLR4, but not of TLR7 or TLR9. (A) BM-derived DCs in GM-CSF-supplemented
cultures were infected with mock or JW strain of MVat 1.5 MOI. At 1 day post-infection (dpi), DCs were treated with either 200 ng/ml of highly pure LPS, 1 mM of
loxoribine (Lox), or 200 ng/ml of CpGDNA (CpG) for 7 h. IL-12p40/p70 produced fromCD11c+DCs for the last 5 hwas assessed by FACS. The% of IL-12-producing
cells andmean fluorescence intensity (MFI) are shown in the box. Experiment repeated three additional times with similar results. (B) BM-DCswere infected as in panel
A and then treated with various amounts of LPS (0, 0.1, 1, 10, 100, or 1000 ng/ml) for 24 h. The intracellular production of IL-12 over the last 5 h was assessed by FACS.
MFI for IL-12 and % of IL-12-producing cells were analyzed, *P value <0.015. Data represent means±SD from triplicates of two independent experiments. (C) DCs
were generated by either GM-CSF or Flt3-L culture system. Their production of IL-12 in response to LPS was analyzed as in panel A. (D) Eight to twelve-week-old tg
mice were injected intravenously (i.v.) with either MV-free B95-8 cell supernatants as a negative control (white bars) or MV (black bars) at a dose of 2×107 TCID50
(5 mice/group). Mice were sacrificed 2 days after inoculation and splenocytes harvested. The ability of CD11c+ DCs inducing IL-12 was analyzed as in panel A. Bars
represent means±SD (n=5), *P=0.001. (E) Expression of TNF-α from BM-DCs infected with either mock (white bars) or MV (black bars) in response to the
treatment of poly(I:C) [p(I:C)], LPS, Lox, or CpG. Data shown represents results confirmed in three independent experiments. (F) Expression of IL-6 from BM-DCs in
response to the treatment of either LPS or CpG DNAwas detected by FACS as above. Bars represent means±SD from triplicates of three independent experiments.
253Rapid Communicationsuppress TLR4-mediated IL-12 production as did wild type MV
(Fig. 3A). However, these specific defective viruses did not
inhibit TLR9-mediated IL-12 synthesis similar to the effect seen
with wild-type MV (data not shown). The results indicate that
MV Vand C proteins are not responsible for IL-12 suppression
mediated via TLR4 signaling.
Human SLAM is a receptor that binds to MV HA (Tatsuo
et al., 2000). DCs from tg mice expressing solely hSLAM
receptor, but not the other MV receptor CD46, provided the
opportunity to determine a possible role of MV HA-hSLAM
interaction in IL-12 suppression observed in DCs. UV-
inactivated MV (UV-MV) barely affected IL-12 production
from hSLAM(−) DCs of non-tg wt mice. In contrast, UV-MV
suppressed IL-12 expression from hSLAM(+) DCs in a viral
dose-dependent manner (Fig. 3B), although the inhibition was
not as strong as seen with replication competent MV (Fig. 3A).
The data indicates that MV HA binding to hSLAM facilitates
TLR4-mediated IL-12 suppression in MV infection. As IL-12suppression was observed in both populations ofMV-uninfected
DCs [MV(−) DCs] andMV(+) DCs when they were treated with
MV (Fig. S3), it is possible that MV HA expressed on MV(+)
cells interacts with hSLAM receptor on MV(−) cells to cause an
inhibition of TLR4-mediated IL-12 synthesis in uninfected cells.
It remains to be investigated if or how MV affects SLAM
signaling involved in TLR4-mediated cytokine production on
DCs (Wang et al., 2004).
In summary, we show for the first time that MV infection of
DCs via SLAM receptor suppresses TLR4-mediated IL-12
induction. This TLR4/IL-12 suppression occurs even in the
presence of the activation of TLR2, TLR3, TLR7, or TLR9. MV
does not interfere with production of TNF-α and IL-6, indicating
that this virus' ability to target IL-12 in the engagement of TLR4
is a specific event. IL-12 is a key cytokine inducing cellular
immune responses to protect host from the harm caused by
pathogenic infections (Trinchieri, 2003). Our data indicates
that MV has devised a clever way to suppress IL-12-mediated
Fig. 2. MV inhibits IL-12 induced by TLR system by co-treatment of LPS. (A) BM-DCs infected with mock or MVwere stimulated with either LPS, CpG, or both LPS
and CpG. IL-12-producing cells were detected as in Fig. 1A. Experiment repeated four additional times with similar results. (B) BM-DCs infected with mock (white
bars) or MV (black bars) were co-treated with CpG and varying concentrations of LPS (0, 0.1, 1, 10, 100, or 1000 ng/ml). MFI for IL-12 was analyzed and compared
between mock-infected DCs (white bars) and MV-infected DCs (black bars) (*P<0.008). (C) LPS or CpG was treated onto Mock (white bars) or MV-infected DCs
(black bars) 1 h before adding the other TLR ligand (CpG or LPS). MFI for IL-12 was analyzed as in panel B (*P<0.002). (D) BM-DCs infected with mock (white
bars) or MV (black bars) were stimulated with either LPS, Lox, or both LPS and Lox. IL-12-producing cells were detected as in Fig. 1B (*P<0.001). (E) BM-DCs
infected with mock (white bars) or MV (black bars) were stimulated with either single agonist of LPS (200 ng/ml), CpG (200 ng/ml), p(I:C) (5 μg/ml), or
peptidoglycan (PGN) (1 μg/ml), or simultaneous co-treatment of p(I:C)+LPS, p(I:C)+CpG, PGN+LPS, or PGN+CpG. IL-12-producing cells were detected as in
panel D (*P<0.002). Bars in panels B, C, D, and E represent means±SD from triplicates (n=3) of at least two independent experiments.
254 Rapid Communicationcellular immune responses by targeting TLR4 even in the
presence of components that activate other TLRs. This likely
represents a selective survival benefit for the virus. Furthermore,
clinically during MV infection the resultant immunosuppression
is often associated with secondary microbial infection and
compromised host defense against such secondary pathogenic
invasions. Our results offer, in part, an explanation why MV-
infected individuals are highly susceptible to opportunistic in-
fections, possibly because MVabrogates the function of DCs in
detecting and delivering danger signals by pathogenic com-
ponents via TLRs to the host immune system (Reis e Sousa,2004; Takeda and Akira, 2004). Such TLR signaling that usually
induces IL-12 to mount effective cellular immune responses is
blocked by MV infection.
Materials and methods
Mice
Mice were maintained in the closed breeding colony of The
Scripps Research Institute. The origin, genotyping, and use of
CD11c–hSLAM tg mice has been reported (Hahm et al., 2004).
Fig. 3. MV HA interaction with SLAM receptor contributes to the suppression
of IL-12. (A) BM-derived DCs were treated with MV, UV-inactivated MV
(UV-MV), or V or C gene-deficient functional recombinant MV [MV-V(−)
and MV-C(−)] at 1.5 MOI. Profile of cytokines IL-12 and TNF-α in DCs
treated with LPS (200 ng/ml) was analyzed as in Fig. 1A. (B) BM-DCs were
obtained from either hSLAM(+) tg mice or non-tg WT mice [hSLAM(−)].
DCs were treated with increasing amount of UV-MV corresponding to 0.1,
0.5, or 2 MOI of infectious MV and the % of DCs producing IL-12 was
detected as above. Data is representative of three independent experiments.
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BM cells were isolated and cultured to generate DCs as
described (Hahm et al., 2005). BM cells obtained were cul-
tured with a supplementation of either 200 U/ml rmGM-CSF
(Peprotech Inc., Rocky Hill, NJ) or 100 ng/ml Flt3-L (Amgen
Inc., Thousand Oaks, CA). After 10 days of culture, non-
adherent cells were pooled by gentle pipetting and then used
as a source of BM-derived DCs. DCs were obtained from
spleens of tg mice after digestion with collagenase D (1 mg/ml,
type II; Sigma Aldrich, St. Louis, MO) at 37 °C for 15 min.
To disrupt T cell–DC complexes, 0.01 M of EDTA was added
and incubation continued for 5 min as described (Hahm et al.,
2005).
Analysis of MV infection
Wild-type MV, JW strain, were passaged on B95-8 cells
(fewer than 10 times) to sufficiently enhance viral titers for
experimental study. MV-C(−) and MV-V(−) were passaged and
titered on Vero cells as described (Patterson et al., 2000) and
were originally a gift from Martin A. Billeter (University of
Zurich). MV was inactivated by UV-exposure for 30 min with a
254-nm UV lamp and loss of infectivity measured by TCID50
assay. For MV-binding to DCs in vitro, BM-derived DCs were
incubated on ice with either MV-free media as a negative
control (mock infection) or MV at 1.0–2.0 multiplicity of
infection (MOI) for 2 h. After washing, cells were recultured in
GM-CSF- or Flt3-L-supplemented media. For in vivo MVinfection, five 8- to 12-week-old tg mice were injected intra-
venously (i.v.) with MV–JW at a dose of 2×107 TCID50 in a
volume of 250 μl. Mice were sacrificed 2 days after
inoculation and splenocytes harvested as above. For a negative
control, MV-free B95-8 cell supernatants were prepared iden-
tically to JW virus stock and used for mock in vivo infection
analysis.
Stimulation of TLRs
DCs were infected with MV for 1 to 2 days and then treated
with ligands for TLRs. Peptidoglycan (Sigma Aldrich, St.
Louis, MO), synthetic analog of double stranded RNA poly
(I:C) (InvivoGen, San Diego, CA), lipopolysaccharide (Alexis
Biochemicals, San Diego, CA), guanosine analog loxoribine
(InvivoGen), and CpG DNA (ODN 1826) (InvivoGen) were
used to stimulate TLR2, TLR3, TLR4, TLR7, and TLR9 on
DCs, respectively. The content of LPS in virus stock or control
stock was analyzed in a bioassay (Hoebe et al., 2003) and
shown to be less than 0.1 ng/ml, which was a minimal limit in
the assay.
ELISA analysis
BM-derived DCs (105 cells/well) were infected with mock or
MV for 24 h. Cell-free culture supernatants were harvested at
24 h after treatment of LPS (10 or 100 ng/ml). Secreted he-
terodimer of IL-12p70, which is composed of p35 and p40
(contemporary nomenclature for p40 subunit is IL-12/23p40)
was measured by a specific ELISA kit (e-Bioscience, San Diego,
CA).
Flow cytometric analysis
Cells were incubated with various fluorochrome-conjugated
antibodies for 20 min on ice in PBS containing 1% FBS and
0.1% sodium azide. Antibodies for this study included specific
for murine CD11c, CD11b, and TLR4/MD2 complex anti-
bodies (BD PharMingen or e-Bioscience, San Diego, CA). For
the detection of surface MV proteins, cells were incubated
with a human polyclonal serum to MV for 20 min, washed
three times, and then stained with PE-conjugated donkey anti-
human IgG antibody (Jackson Immunoresearch Laboratories)
(Hahm et al., 2004). For intracellular staining of cytokines,
cells were treated with 4 μg/ml Brefeldin A (Sigma Aldrich)
for the last 5 h of TLR stimulation, fixed and permeabilized
with 4% paraformaldehyde and 0.1% saponin in HBSS, and
then stained with antibodies against IL-12 p40/p70, IL-6, or
TNF-α (BD PharMingen or e-Bioscience) in permeabilization
buffer (0.1% saponin and 1% FBS in PBS). Antibody against
IL-12(p40/p70) (BD PharMingen) reacts with both free and
complexed (homodimer p80 and heterodimer p70) forms of
the p40 subunit (IL-12/23p40) of mouse IL-12 detecting both
p40 subunit (IL-12/23p40) and p70 heterodimer. Fluorescent
cells were acquired with a FACSCalibur™ flow cytometer
(Becton Dickinson, San Jose, CA) then analyzed with FlowJo
software.
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